These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 36609061)
1. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. Zengin ZB; Govindarajan A; Salgia N; Sayegh N; Tripathi N; Muddasani R; Chehrazi-Raffle A; Feng M; Mercier BD; Ladbury C; Hao C; Salgia S; Chawla N; Meza L; Malhotra J; Dizman N; Hsu J; Castro DV; Barragan-Carrillo R; Ebrahimi H; Philip EJ; Chang M; Zhang J; Byron S; Lyou Y; Dorff T; Pal SK; Dandapani S Eur Urol Oncol; 2023 Aug; 6(4):447-450. PubMed ID: 36609061 [TBL] [Abstract][Full Text] [Related]
2. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998 [TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993 [TBL] [Abstract][Full Text] [Related]
4. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125 [TBL] [Abstract][Full Text] [Related]
5. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659 [TBL] [Abstract][Full Text] [Related]
7. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Masini C; Iotti C; De Giorgi U; Bellia RS; Buti S; Salaroli F; Zampiva I; Mazzarotto R; Mucciarini C; Vitale MG; Bruni A; Lohr F; Procopio G; Caffo O; Nole F; Morelli F; Baier S; Buttigliero C; Ciammella P; Timon G; Fantinel E; Carlinfante G; Berselli A; Pinto C Eur Urol; 2022 Mar; 81(3):274-282. PubMed ID: 34602312 [TBL] [Abstract][Full Text] [Related]
9. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397 [TBL] [Abstract][Full Text] [Related]
10. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494 [TBL] [Abstract][Full Text] [Related]
11. Radiation Therapy for Patients with Advanced Renal Cell Carcinoma. Miccio JA; Oladeru OT; Jun Ma S; Johung KL Urol Clin North Am; 2020 Aug; 47(3):399-411. PubMed ID: 32600541 [TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061 [TBL] [Abstract][Full Text] [Related]
14. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. Onal C; Hurmuz P; Guler OC; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G Clin Transl Oncol; 2022 Aug; 24(8):1533-1541. PubMed ID: 35119653 [TBL] [Abstract][Full Text] [Related]
15. Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Chow J; Hoffend NC; Abrams SI; Schwaab T; Singh AK; Muhitch JB Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23721-23729. PubMed ID: 32900949 [TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy. Panje C; Andratschke N; Brunner TB; Niyazi M; Guckenberger M Strahlenther Onkol; 2016 Dec; 192(12):875-885. PubMed ID: 27778052 [TBL] [Abstract][Full Text] [Related]
17. Role of Radiation in Treatment of Renal Cell Carcinoma. Leeman JE Hematol Oncol Clin North Am; 2023 Oct; 37(5):921-924. PubMed ID: 37246085 [TBL] [Abstract][Full Text] [Related]
18. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031 [TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study. Onal C; Oymak E; Guler OC; Tilki B; Yavas G; Hurmuz P; Yavas C; Ozyigit G Strahlenther Onkol; 2023 May; 199(5):456-464. PubMed ID: 36450836 [TBL] [Abstract][Full Text] [Related]
20. A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Singh AK; Winslow TB; Kermany MH; Goritz V; Heit L; Miller A; Hoffend NC; Stein LC; Kumaraswamy LK; Warren GW; Bshara W; Odunsi K; Matsuzaki J; Abrams SI; Schwaab T; Muhitch JB Clin Cancer Res; 2017 Sep; 23(17):5055-5065. PubMed ID: 28630212 [No Abstract] [Full Text] [Related] [Next] [New Search]